Conservin nucleic acid molecules and compositions

• US 5,807,708 A
• Filed: 07/30/1996
• Issued: 09/15/1998
• Est. Priority Date: 07/30/1996
• Status: Expired due to Fees

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: Falb, Dean A., Gimeno, Carlos J.
• Primary Examiner(s): Walsh, Stephen
• Assistant Examiner(s): Kaufman, Claire M.
• Application Number:
  US08/688,609
• Time in Patent Office: 777 Days
• Field of Search: 536/23.5, 536/23.1, 435/320.1, 435/325, 435/252.3, 435/254.11, 435/69.1, 435/235.1, 424/450
• US Class Current: 435/69.1
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/495 Transforming growth factor [TGF]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.

Claims

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide which is at least 92.5% identical to the amino acid sequence of SEQ ID NO:

3 or 6 and which binds in a yeast two hybrid assay with the polypeptide encoded by the fchd 534 gene deposited with NRRL as Accession Number B-21458.

2. The nucleic acid molecule of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:

3 or 6.

3. The nucleic acid molecule of claim 1, wherein the nucleotide sequence is at least 75% identical to the nucleotide sequence of SEQ ID NO:

1 or 4.

4. The nucleic acid molecule of claim 3, wherein the nucleotide sequence is at least 80% identical to the nucleotide sequence of SEQ ID NO:

1 or 4.

5. The nucleic acid molecule of claim 4, wherein the nucleotide sequence is at least 90% identical to the nucleotide sequence of SEQ ID NO:

1 or 4.

6. The nucleic acid molecule of claim 5, which comprise the nucleotide sequence of SEQ ID NO:

1 or 4.

19. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid molecule as in claim 1, 2, 3, 4, 5, 13, 14, or 15.

20. The nucleic acid molecule as in claim 1, 2, 3, 4, 5, 13, 14, or 15, which is genomic DNA.

21. The nucleic acid molecule as in claim 1, 2, 3, 4, 5, 13, 14, or 15, which is cDNA.

22. The nucleic acid molecule as in claim 1, 2, 3, 4, 5, 13, 14, or 15, which is RNA.

23. A vector comprising the nucleic acid molecule as in claim 1, 2, 3, 4, 5, 13, 14, or 15.

24. The vector of claim 23, which is a recombinant expression vector.

25. A host cell containing the vector of claim 23.

26. A host cell containing the recombinant expression vector of claim 24.

39. The nucleic acid molecule of claim 1, wherein the nucleotide sequence is at least 85% identical to the nucleotide sequence of SEQ ID NO:

2.

40. The nucleic acid molecule of claim 39, wherein the nucleotide sequence is at least 90% identical to the nucleotide sequence of SEQ ID NO:

2.

41. The nucleic acid molecule of claim 40, wherein the nucleotide sequence is at least 95% identical to the nucleotide sequence of SEQ ID NO:

2.

42. The nucleic acid molecule of claim 41, which comprises the nucleotide sequence of SEQ ID NO:

2.

44. The nucleic acid molecule of claim 1, wherein the nucleotide sequence is at least 95% identical to the nucleotide sequence of SEQ ID NO:

5.

45. The nucleic acid molecule of claim 44, which comprises the nucleotide sequence of SEQ ID NO:

5.

47. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid molecule as in claim 39, 40, 41, 42, 43, 44, 45, or 46.

48. The nucleic acid molecule as in claim 39, 40, 41, 42, 43, 44, 45, or 46, which is genomic DNA.

49. The nucleic acid molecule as in claim 39, 40, 41, 42, 43, 44, 45, or 46, which is cDNA.

50. The nucleic acid molecule as in claim 39, 40, 41, 42, 43, 44, 45, or 46, which is RNA.

51. A vector comprising the nucleic acid molecule as in claim 39, 40, 41, 42, 43, 44, 45, or 46.

52. The vector of claim 51, which is a recombinant expression vector.

53. A host cell containing the vector of claim 51.

54. A host cell containing the recombinant expression vector of claim 52.

7. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide which is at least 92.5% identical to the amino acid sequence encoded by the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049 and which binds in a yeast two hybrid assay with the polypeptide encoded by the fchd 534 gene deposited with NRRL as Accession Number B-21458.

8. The nucleic acid molecule of claim 7, wherein the polypeptide comprises the amino acid sequence encoded by the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

9. The nucleic acid molecule of claim 7, wherein the nucleotide sequence is at least 75% identical to the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

10. The nucleic acid molecule of claim 9, wherein the nucleotide sequence is it least 80% identical to the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

11. The nucleic acid molecule of claim 10, wherein the nucleotide sequence is at least 90% identical to the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

12. The nucleic acid molecule of claim 11, wherein the which comprises the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

27. An isolated nucleic acid molecule comprising a nucleotide sequence which is complementary to the nucleotide sequence of the nucleic acid molecule as in claim 7, 8, 9, 10, 11, 6, 12, 16, 17, or 18.

28. The nucleic acid molecule as in claim 7, 8, 9, 10, 11, 6, 12, 16, 17, or 18, which is genomic DNA.

29. The nucleic acid molecule as in claim 7, 8, 9, 10, 11, 6, 12, 16, 17, or 18, which is cDNA.

30. The nucleic acid molecule as in claim 7, 8, 9, 10, 11, 6, 12, 16, 17, or 18, which is RNA.

31. A vector comprising the nucleic acid molecule as in claim 7, 8, 9, 10, 11, 6, 12, 16, 17, or 18.

32. The vector of claim 31, which is a recombinant expression vector.

33. A host cell containing the vector of claim 31.

34. A host cell containing the recombinant expression vector of claim 32.

13. An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 75% identical to the nucleotide sequence of SEQ ID NO:

1 or 4.

14. The nucleic acid molecule of claim 13, wherein the nucleotide sequence is at least 80% identical to the nucleotide sequence of the SEQ ID NO:

1 or 4.

15. The nucleic acid molecule of claim 14, wherein the nucleotide sequence is at least 90% identical to the nucleotide sequence of SEQ ID NO:

1 or 4.

16. An isolated nucleic acid molecule comprising a nucleotide sequence is at least 75% identical to the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

17. The nucleic acid molecule of claim 16, wherein the nucleotide sequence is at least 80% identical to the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

18. The nucleic acid molecule of claim 17, wherein the nucleotide sequence is at least 90% identical to the nucleotide sequence of the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049.

35. A method for producing a polypeptide comprising culturing a host cell containing a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:

3 or 6 in a suitable medium to thereby produce the polypeptide.

36. The method of claim 35, further comprising isolating the polypeptide from the medium or the host cell.

37. A method for producing a polypeptide comprising culturing a host cell containing a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence encoded by the human DNA insert of the plasmid deposited with ATCC®

as Accession Number 98048 or 98049 in a suitable medium to thereby produce the polypeptide.

38. The method of claim 37, further comprising isolating the polypeptide from the medium or the host cell.

43. An isolated nucleic acid molecule comprising a nucleotide sequence which at least 85% identical to the nucleotide sequence of SEQ ID NO:

2.

46. An isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:

5.